本帖最后由 老马 于 2013-3-13 13:43 编辑
. u$ r* s: i' @& m3 R0 v6 z6 h5 L2 l$ s( h! Y7 T
健择（吉西他滨）+顺铂+阿瓦斯汀
0 d9 g5 E$ F6 B! I Gemzar +Cisplatin + Avastin3 m1 J. [6 ?+ z8 E3 g. J
http://annonc.oxfordjournals.org/content/21/9/1804.full( {0 r f6 d b4 Q/ s( [6 n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 0 t8 X/ l) `. z/ w* V
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. {# ~4 u9 ]# ^( aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ n# t" ^/ N2 ~$ V3 R7 }3 n' _
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
( N7 q; t' h8 Q( g) E: M华为网盘附件：- S) {+ e! [9 V
【华为网盘】ava.JPG
5 _6 X! a" c8 T. ^0 ^1 W |
汇总4月最新：临床试验招募| 小细胞
"化疗±免疫后进展了，还能怎么办？"——这是许多小细胞肺癌患者和家属的困境。
临
母亲肺腺癌晚期骨转移，EGFR21突变，
母亲1970年出生，56周岁，身高163cm，体重98kg（196斤）。2025年9月23日肺炎住院，胸
肺癌术后五年，脑膜转移治疗三年，伏
2025年8月14日更新: 终于输液港血培养结果为阴性了，14天美平消炎出院了，昨天开始双
从6个月到1400多天：一位晚期肺癌患
2026年全国肿瘤防治宣传周（4月15日-21日）即将到来，今年中国抗癌协会的主题是“肿瘤
补血食谱—鸭血二菜
血红蛋白低，需补铁补血，鸭血中含有丰富的血红素铁，相对植物性食物中的铁，吸收利用
11011102001537 )
显身卡
